Abstract
Abstract BACKGROUND: Cardiovascular disease remains one of the leading causes of morbidity and mortality. The need for the cardiovascular prevention is undeniable. Numerous risk scores are available for the same and current guideline shows the need for starting the statin therapy in high-risk individuals. AIM: To assess the clinical utility of CT coronary calcium scoring in real world. OBJECTIVE: To assess the use of CT coronary calcium scoring in patients with low to intermediate 10-year risk by modified Framingham risk score. MATERIALS AND METHODS: It was a cross-sectional retrospective study conducted at a tertiary cardiac care centre of Delhi from January 2024 to May 2024. Two hundred and twenty consecutive subjects were found to have low (10-year risk <10%) to intermediate (10-year risk 10%–19%) by modified Framingham risk score (FRS) based on conventional risk factor profiling and were advised CT coronary calcium scoring were selected. Based on calcium score, the subjects were reclassified into “low risk” (Agatston Score 0–100) or “high risk” (Agatston score >100). RESULTS: CTCA score of 129 patients with low- and intermediate modified FRS reclassified them into low risk (72.8%), high risk (6.2%), and very high risk (9.3%). Overall, 15.5% of patients at low and intermediate risk by modified FRS were reclassified as high risk or very high risk after calcium scoring. CONCLUSION: The re-evaluation of ASCVD risk by CT coronary calcium score prompted us to start statin therapy in 15.5% of our patients which is likely to reduce the incidence of future cardiovascular events.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call